L’Oréal Luxe Group launches makeup brand co-created by YouTube beauty vlogger, online community
NEW YORK — Em michelle phan, a start-up brand from the L’Oréal Luxe group, marks the first makeup line co-created by a community of beauty lovers and YouTube beauty vlogger Michelle Phan.
The line launched this month and is available at emcosmetics.com.
"Beauty lovers are increasingly consuming and sharing information digitally, through online communities. We saw the power of these communities and wanted to meet them where they live — online. Michelle Phan’s expertise in makeup, plus her passion for teaching and empowering women has made her a digital phenomenon. She represents exactly what this line is all about — community, empowerment, artistry," stated Carol Hamilton, president of L’Oréal Luxe.
Phan is self-taught and was one of the first beauty vloggers to produce story-driven makeup tutorials. The YouTube beauty guru began uploading tutorials in 2007. To-date, she has garnered nearly 1 billion views and has 4.5 million subscribers.
Em, a Vietnamese word meaning "you," is used affectionately to address loved ones including a little sister, girlfriend or elder. It is also literally and figuratively a reflection of "me" — it is a makeup line that reflects the needs of Phan’s community. The community has been a part of every piece of the brand, providing input on launch products, shade names and product packaging. Community members also appear in package design, brand photography and on the em michelle phan website.
At launch, em michelle phan will be sold exclusively online to U.S. customers at emcosmetics.com. Created to offer a social e-commerce experience, the site will allow beauty lovers to interact with friends and other consumers, provide feedback on creating looks and the products and share on their own social media channels. The makeup brand’s site is designed to enhance the digital shopping experience.
The em michelle phan line is comprised of more than 250 different SKUs. Hero products include:
- The Life Palette – Refillable eye shadow, cheek and lip palette with 36 shades each, themed around specific life moments and beauty stories including Love Life, Day Life, Beach Life, Career Life, Party Life and Night Life; priced at $75
- Artistic Cheek Color Palette available in 10 palettes; priced at $28
- Lip Color Mixing Palette available in six palettes; priced at $28
- Artistic Eye Color Palette available in 15 palettes; priced at $38
- The Great Cover Up – The ultimate creamy concealer in eight shades; priced at $19
- Makeup Mood Enhancer – Illuminating skin filter in five shades; priced at $25
- Pillow Plush – Cushiony lip balm in seven shades; priced at $15
- Chiaroscuro – Contour and highlighting stick in four shades; priced at $25
- Waterliner – Intense color eye liner in 12 shades; priced at $20
CVS Caremark, Dovetail Health collaborate with Aetna in new pilot program
HARTFORD, Conn. and WOONSOCKET, R.I. — Aetna has announced a new pilot program, dubbed the Aetna Rx Home Success Program, which is supported by CVS Caremark.
The Aetna Rx Home Success Program works with CVS Caremark pharmacists and Dovetail Health to support Aetna members who are taking multiple medications. The program helps members manage their health through personal support from a pharmacist — including offering in-home consultations — and focuses on those who have recently been discharged from a hospital, nursing home or rehabilitation facility.
The six-month pilot program will be offered in the District of Columbia, Maryland and Northern Virginia. Readmission rates and member satisfaction of enrollees will be measured at the conclusion of the pilot.
How it works: Members who decide to enroll in the Aetna Rx Home Success Program are contacted by a pharmacist who will work with them to schedule an in-home visit or a detailed phone consultation. The pharmacist will review any new and/or pre-existing medications and help create a detailed care plan with the member and their doctor. The pharmacist will address potential medication-related issues, identify gaps in care and educate members about their medicine(s). The pharmacist also will consider other risk factors, including chronic conditions, home safety and will aid in arranging physician follow-up visits.
Hospital readmissions due to not properly taking their medication affect nearly 3.5 million patients and result in about $15.2 billion dollars in healthcare costs each year. Aetna’s approach to health care, blending the expertise of CVS Caremark and a Dovetail Health pharmacist, aims to provide a complete circle of care, ensuring positive health outcomes for its members.
"We look forward to piloting this program with Aetna as high rates of hospital readmissions result in increased costs for the patient and the payer, which can negatively impact a patient’s health outcomes," stated Troyen Brennan, EVP and chief medical officer for CVS Caremark. "Many patients who are newly discharged from a hospital or rehab facility are taking multiple medications. Trying to navigate multiple treatment guidelines provided by the patient’s primary care physician and the treatment facility discharge team can be overwhelming. Our research shows that the intervention of a clinical pharmacist helps patients better understand their medications and avoid potential setbacks to recovery after returning home."
Members are identified by an Aetna case manager as either "high risk" or "moderate risk" for hospital readmission. Within two days of discharge, high-risk members are contacted to schedule an in-home medication review performed by a Dovetail pharmacist. CVS Caremark pharmacists contact the moderate risk members to schedule a medication review over the phone. All members receive ongoing support in the form of follow-up phone calls for a 30-day period. Aetna case management nurses for continuing care coordination also mentor members. After the 30 days, the member will be discharged from the program and moved back to Aetna Case Management for continued follow-up and care.
Study: Type 2 diabetes market competition heats up amid disease rate increase
MOUNTAIN VIEW, Calif. — A global population of patients with prediabetes that is three times the size of those who already have Type 2 diabetes has led to intense competition between drug makers to launch drugs to treat the disease, according to a new report.
Frost & Sullivan’s report, "Analysis of the Global Type 2 Diabetes Therapeutic Market," found that 15 new drugs are in late-stage clinical trials or awaiting regulatory review. According to the American Diabetes Association, 25.8 million people in the United States are living with diabetes, mostly with Type 2, which is lifestyle-related, while 79 million people have prediabetes, defined as a condition in which patients are at risk of developing full-blown Type 2 diabetes.
"The Type 2 diabetes market continually advances, primarily due to the dominance of obesity," Frost & Sullivan life sciences global program director Jennifer Lazar Brice said. "Current studies of this increasingly competitive market are limited in their approach. Seeing this missed opportunity, we began addressing such markets in a new way. Our repositioned life sciences program includes therapeutic product and pipeline analyses and services focused on our clients’ proactive competitive intelligence goals."
The report found that a "tremendous" increase in Type 2 diabetes is in store, and the industry needs better ways to prevent the disease from progressing. This includes identifying the precursors to fully developed diabetes through preventive therapy.